NASDAQ:NYMX Nymox Pharmaceutical - NYMX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nymox Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. $0.44 -0.01 (-2.21%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.43▼$0.4750-Day Range$0.28▼$0.7452-Week Range$0.19▼$2.10Volume127,815 shsAverage Volume49,261 shsMarket Capitalization$40.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Nymox Pharmaceutical (NASDAQ:NYMX) StockNymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.Read More Receive NYMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address NYMX Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comNymox Pharmaceutical (NASDAQ:NYMX) Receives New Coverage from Analysts at StockNews.comJanuary 6, 2023 | finance.yahoo.comNYMOX Appeals Deficiency LetterFebruary 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 5, 2022 | finance.yahoo.comNYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPHSeptember 27, 2022 | finance.yahoo.comA Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider increased their holdings by 32% last yearAugust 17, 2022 | nasdaq.comWe Think Nymox Pharmaceutical (NASDAQ:NYMX) Needs To Drive Business Growth CarefullyJuly 15, 2022 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 2.15%July 15, 2022 | finance.yahoo.comNYMOX Updates ShareholdersFebruary 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! July 14, 2022 | finance.yahoo.comNYMOX Receives Deficiency Letter from NASDAQMay 23, 2022 | marketwatch.comNymox Pharmaceutical Down 64% on FDA Refusal to File LetterMay 23, 2022 | seekingalpha.comNYMOX down 46% on Refuse to File letter from FDA for fexapotide for enlarged prostateMay 23, 2022 | marketwatch.comNymox Application for Fexapotide Triflutate Rejected by FDA >NYMXMay 23, 2022 | benzinga.comWhy Nymox Pharma Shares Sinking to 52-Week Low?May 9, 2022 | uk.investing.comExecutives Buy Around $5M Of 4 Penny StocksMay 6, 2022 | nasdaq.comFriday 5/6 Insider Buying Report: ALGN, NYMXApril 4, 2022 | finance.yahoo.comNymox Announces Closing of $6.4 Million FinancingApril 3, 2022 | finance.yahoo.comA Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider increased their holdings by 1.1% last yearMarch 18, 2022 | msn.comHere's Why Nymox Pharmaceuticals Shares Are MovingMarch 18, 2022 | baystreet.caNymox Direct OfferingMarch 18, 2022 | seekingalpha.comNymox Pharmaceutical announces $5M registered direct offeringMarch 18, 2022 | finance.yahoo.comNymox Announces $5 Million Registered Direct OfferingMarch 3, 2022 | marketwatch.comNymox Seeks FDA OK for Enlarged Prostate Treatment >NYMXMarch 3, 2022 | seekingalpha.comNymox stock rises 8% as it files for FDA approval of drug treating enlarged prostateMarch 3, 2022 | finance.yahoo.comNYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide TriflutateJanuary 3, 2022 | nasdaq.comInsiders at Nymox Pharmaceutical Corporation (NASDAQ:NYMX) recouped some losses this week after buying this year, still down US$31kDecember 31, 2021 | nasdaq.comNymox Pharmaceutical Corp Shares Near 52-Week Low - Market MoverSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NYMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address NYMX Company Calendar Last Earnings11/14/2022Today2/05/2023Next Earnings (Estimated)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NYMX CUSIPN/A CIK1018735 Webwww.nymox.com Phone(800) 936-9669Fax514-332-2227Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,902.43% Return on Assets-312.63% Debt Debt-to-Equity RatioN/A Current Ratio1.24 Quick Ratio1.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-44.29Miscellaneous Outstanding Shares90,510,000Free Float41,637,000Market Cap$40.09 million OptionableOptionable Beta0.71 Key ExecutivesPaul AverbackChairman, President & Chief Executive OfficerRandall J. LanhamCOO, Secretary, Director & General CounselRussell I. ThomsonVice President-Quality & Regulatory AffairsKey CompetitorsBiomericaNASDAQ:BMRATrinity BiotechNASDAQ:TRIBOncoCyteNASDAQ:OCXARCA biopharmaNASDAQ:ABIOImmuCellNASDAQ:ICCCView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 100 shares on 2/2/2023Ownership: 0.000%Group One Trading L.P.Bought 10,200 shares on 11/9/2022Ownership: 0.000%James George RobinsonBought 1,151,515 shares on 5/2/2022Total: $1.90 M ($1.65/share)View All Insider TransactionsView All Institutional Transactions NYMX Stock - Frequently Asked Questions How have NYMX shares performed in 2023? Nymox Pharmaceutical's stock was trading at $0.3233 at the beginning of 2023. Since then, NYMX shares have increased by 37.0% and is now trading at $0.4429. View the best growth stocks for 2023 here. When is Nymox Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our NYMX earnings forecast. How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its quarterly earnings data on Monday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC). What is Nymox Pharmaceutical's stock symbol? Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX." Who are Nymox Pharmaceutical's major shareholders? Nymox Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Nymox Pharmaceutical? Shares of NYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nymox Pharmaceutical's stock price today? One share of NYMX stock can currently be purchased for approximately $0.44. How much money does Nymox Pharmaceutical make? Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $40.09 million. The biopharmaceutical company earns $-12,540,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis. How can I contact Nymox Pharmaceutical? Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227. This page (NASDAQ:NYMX) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.